Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

Jeffrey L. Cummings, Stuart Isaacson, Roger Mills et al. · The Lancet · 2013 · 942 citations

Medicine, Pharmacology, Pharmacotherapy +14

Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment

Joseph McEvoy · American Journal of Psychiatry · 2006 · 820 citations

Pharmacy, Pharmacotherapy, Psychiatry +16

Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment

Joseph P. McEvoy, Jeffrey A. Lieberman, T. Scott Stroup et al. · American Journal of Psychiatry · 2006 · 755 citations

Pharmacy, Pharmacotherapy, Psychiatry +16

Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis

Herbert Y. Meltzer, Roger Mills, Stephen Revell et al. · Neuropsychopharmacology · 2009 · 295 citations

Medicine, Pharmacology, Pharmacotherapy +13

Tardive dyskinesia risk with first‐ and second‐generation antipsychotics in comparative randomized controlled trials: a meta‐analysis

Maren Carbon, John M. Kane, Stefan Leucht et al. · World Psychiatry · 2018 · 205 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17